Salarius Announces Closing of $6.2 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
August 03 2020 - 4:05PM
Salarius Pharmaceuticals, Inc.. (Nasdaq: SLRX) today announced the
closing of its previously announced underwritten public offering of
5,130,390 shares of its common stock, including 669,181 shares sold
pursuant to the exercise in full of the underwriters’ option to
purchase additional shares, at the public offering price of $1.20
per share. As a result of the underwriters’ over-allotment
option exercise, the aggregate gross proceeds to Salarius from the
offering, before deducting underwriting discounts and commissions
and other offering expenses, was approximately $6.2 million.
Ladenburg Thalmann & Co. Inc. acted as
sole book-running manager in connection with the public
offering.
The securities were offered pursuant to a
registration statement on
Form S-3 (File No. 333-231010), which was
declared effective by the United States Securities and Exchange
Commission (the “SEC”) on May 17, 2019. A copy of the final
prospectus supplement and accompanying prospectus relating to the
offering may be obtained be obtained at the SEC’s website at
www.sec.gov or from Ladenburg Thalmann & Co. Inc., Attn:
Prospectus Department, 277 Park Avenue, 26th Floor, New York, New
York 10172, by calling (212) 409-2000.
This press release shall not constitute an offer
to sell or the solicitation of an offer to buy these securities,
nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Salarius Pharmaceuticals,
Inc.Salarius Pharmaceuticals, Inc. is a clinical-stage
oncology company targeting cancers caused by dysregulated gene
expression, or epigenetic causes of cancers, and is developing
treatments for patients that need them the most. Epigenetics
refers to the regulatory system that affects gene expression.
Salarius’ lead candidate, seclidemstat, is currently in clinical
development for treating Ewing sarcoma, for which it has Fast Track
Designation, Orphan Drug Designation and Rare Pediatric Disease
Designation by the U.S. Food and Drug Administration.
Salarius is also developing seclidemstat for a number of cancers,
with a second Phase 1/2 clinical study in advanced solid tumors,
including prostate, breast and ovarian cancers.
Contact
Investor RelationsTiberend Strategic Advisors,
Inc. Maureen McEnroe, CFA/Miriam Miller(212) 375-2664 /
2694mmcenroe@tiberend.commmiller@tiberend.com
Media RelationsTiberend Strategic Advisors,
Inc.Johanna Bennett(212) 375-2686 jbennett@tiberend.com
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
From Sep 2023 to Sep 2024